Sunday 18 October 2026
Export GNLX’s income statement to Excel — free account
Genelux Corporation
GNLX Healthcare Biotechnology
Genelux Corporation’s revenue for fiscal 2025 (year ended December 2025) was $8,000.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, EPS fell 5.00% and free cash flow fell 11.2%, each against the same quarter a year earlier.
2.42
0.06
−2.42%
Follow GNLX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (177.93%) | (127.28%) | (170.00%) | (123.35%) |
+8 more TTM periods Free account |
|
| (121.80%) | (94.12%) | (119.62%) | (97.69%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(226.02%) | (148.83%) | (290.25%) | (174.94%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.64) | (0.63) | (0.71) | (0.64) | |
Free Cash Flow |
(28.68) | (27.88) | (26.37) | (24.13) | |
Capital Expenditures |
(3.41) | (1.99) | (1.10) | (0.76) | |
| Other line items | |||||
Cash ROIC |
(82.46%) | (56.75%) | (100.87%) | (61.08%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.71 | 0.77 | 0.79 | 0.73 | |
Depreciation/Fixed assets |
(0.01) | 0.01 | 0.01 | (0.08) | |
Capex/Depreciation |
77.41 | (52.34) | (61.00) | 5.12 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.56) | (0.59) | (0.68) | (0.62) | |
Capex per Share |
(0.08) | (0.04) | (0.03) | (0.02) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates